Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria
Copyright © 2021 Feng, Liu, Wang, Zhang, Sun, Li, Wang, Liu and Cao..
Colistin-resistant (Col-R) bacteria are steadily increasing, and are extremely difficult to treat. New drugs or therapies are urgently needed to treat infections caused by these pathogens. Combination therapy with colistin and other old drugs, is an important way to restore the activity of colistin. This study aimed to investigate the activity of colistin in combination with the anti-rheumatic drug auranofin against Col-R Gram-negative bacteria. The results of checkerboard analysis demonstrated that auranofin synergized with colistin against Col-R Gram-negative bacteria. Time-kill assays showed significant synergistic antimicrobial activity of colistin combined with auranofin. Electron microscopy revealed that the combination resulted in more cellular structural alterations compared to each drug alone. Auranofin enhanced the therapeutic effectiveness of colistin in mouse peritoneal infection models. These results suggested that the combination of colistin and auranofin might be a potential alternative for the treatment of Col-R Gram-negative bacterial infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in microbiology - 12(2021) vom: 26., Seite 676414 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feng, Xiaoxuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Auranofin |
|---|
| Anmerkungen: |
Date Revised 13.07.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fmicb.2021.676414 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32794711X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32794711X | ||
| 003 | DE-627 | ||
| 005 | 20231225201919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmicb.2021.676414 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM32794711X | ||
| 035 | |a (NLM)34248888 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feng, Xiaoxuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.07.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Feng, Liu, Wang, Zhang, Sun, Li, Wang, Liu and Cao. | ||
| 520 | |a Colistin-resistant (Col-R) bacteria are steadily increasing, and are extremely difficult to treat. New drugs or therapies are urgently needed to treat infections caused by these pathogens. Combination therapy with colistin and other old drugs, is an important way to restore the activity of colistin. This study aimed to investigate the activity of colistin in combination with the anti-rheumatic drug auranofin against Col-R Gram-negative bacteria. The results of checkerboard analysis demonstrated that auranofin synergized with colistin against Col-R Gram-negative bacteria. Time-kill assays showed significant synergistic antimicrobial activity of colistin combined with auranofin. Electron microscopy revealed that the combination resulted in more cellular structural alterations compared to each drug alone. Auranofin enhanced the therapeutic effectiveness of colistin in mouse peritoneal infection models. These results suggested that the combination of colistin and auranofin might be a potential alternative for the treatment of Col-R Gram-negative bacterial infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a auranofin | |
| 650 | 4 | |a colistin | |
| 650 | 4 | |a colistin-resistant | |
| 650 | 4 | |a combination therapy | |
| 650 | 4 | |a repurposing | |
| 650 | 4 | |a synergistic effect | |
| 700 | 1 | |a Liu, Shuai |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yulin |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Lingxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Haibo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chunlei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yingmei |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Bin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in microbiology |d 2010 |g 12(2021) vom: 26., Seite 676414 |w (DE-627)NLM208040617 |x 1664-302X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g day:26 |g pages:676414 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fmicb.2021.676414 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |b 26 |h 676414 | ||